Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Sequencing of Taxanes and New Androgen-targeted Therapies in Metastatic Castration-resistant Prostate Cancer: Results of the International Multicentre Retrospective CATS Database.

Delanoy N, Hardy-Bessard AC, Efstathiou E, Le Moulec S, Basso U, Birtle A, Thomson A, Krainer M, Guillot A, De Giorgi U, Hasbini A, Daugaard G, Bahl A, Chowdhury S, Caffo O, Beuzeboc P, Spaeth D, Eymard JC, Fléchon A, Alexandre J, Helissey C, Butt M, Priou F, Lechevallier É, Deville JL, Goupil MG, Morales R, Thiery-Vuillemin A, Gavrikova T, Barthelemy P, Sella A, Fizazi K, Baciarello G, Fererro JM, Laguerre B, Verret B, Hans S, Oudard S.

Eur Urol Oncol. 2018 Dec;1(6):467-475. doi: 10.1016/j.euo.2018.05.009. Epub 2018 Jun 8.

PMID:
31158090
2.

Synthetic lethality guiding selection of drug combinations in ovarian cancer.

Heinzel A, Marhold M, Mayer P, Schwarz M, Tomasich E, Lukas A, Krainer M, Perco P.

PLoS One. 2019 Jan 25;14(1):e0210859. doi: 10.1371/journal.pone.0210859. eCollection 2019.

3.

Synthetic lethal combinations of low-toxicity drugs for breast cancer identified in silico by genetic screens in yeast.

Marhold M, Tomasich E, Schwarz M, Udovica S, Heinzel A, Mayer P, Horak P, Perco P, Krainer M.

Oncotarget. 2018 Nov 20;9(91):36379-36391. doi: 10.18632/oncotarget.26372. eCollection 2018 Nov 20.

4.

LUBAC and ABIN-1 Modulate TRAIL-Based NF-κB Induction in Human Embryonic Kidney 293 Cells.

Dorn S, Schoergenhofer C, Krainer M, Müller M, Jilma B.

Biores Open Access. 2018 May 1;7(1):81-89. doi: 10.1089/biores.2018.0006. eCollection 2018.

5.

Analysis of hematological parameters as prognostic markers for toxicity and survival of 223Radium treatment.

Leisser A, Nejabat M, Hartenbach M, Agha Mohammadi Sareshgi R, Shariat S, Kramer G, Krainer M, Hacker M, Haug AR.

Oncotarget. 2018 Mar 5;9(22):16197-16204. doi: 10.18632/oncotarget.24610. eCollection 2018 Mar 23.

6.

Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.

Thibault C, Eymard JC, Birtle A, Krainer M, Baciarello G, Fléchon A, Le Moulec S, Spaeth D, Laguerre B, Caffo O, Deville JL, Beuzeboc P, Hasbini A, Gross-Goupil M, Helissey C, Bennamoun M, Hardy-Bessard AC, Oudard S.

Eur J Cancer. 2018 Jul;97:41-48. doi: 10.1016/j.ejca.2018.03.008. Epub 2018 Apr 7.

PMID:
29636272
7.

Efficient leukocyte depletion by a novel microfluidic platform enables the molecular detection and characterization of circulating tumor cells.

Obermayr E, Maritschnegg E, Agreiter C, Pecha N, Speiser P, Helmy-Bader S, Danzinger S, Krainer M, Singer C, Zeillinger R.

Oncotarget. 2017 Nov 28;9(1):812-823. doi: 10.18632/oncotarget.22549. eCollection 2018 Jan 2.

8.

Hematopoiesis is prognostic for toxicity and survival of 223Radium treatment in patients with metastatic castration-resistant prostate cancer.

Leisser A, Nejabat M, Hartenbach M, Duan H, Shariat SF, Kramer G, Krainer M, Hacker M, Haug AR.

Hell J Nucl Med. 2017 Sep-Dec;20 Suppl:157.

PMID:
29324927
9.

The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna.

Kiesewetter B, Raderer M, Prager GW, Fuereder T, Marosi C, Preusser M, Krainer M, Locker GJ, Brodowicz T, Zielinski CC.

ESMO Open. 2017 Jul 16;2(3):e000166. doi: 10.1136/esmoopen-2017-000166. eCollection 2017.

10.

Increased genitourinary fistula rate after bevacizumab in recurrent cervical cancer patients initially treated with definitive radiochemotherapy and image-guided adaptive brachytherapy.

Sturdza A, Hofmann S, Kranawetter M, Polterauer S, Grimm C, Krainer M, Kirisits C, Pötter R, Reinthaller A, Schwameis R.

Strahlenther Onkol. 2017 Dec;193(12):1056-1065. doi: 10.1007/s00066-017-1178-x. Epub 2017 Jul 18.

11.

The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna.

Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R, Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger M, Zielinski CC.

ESMO Open. 2016 Jul 4;1(4):e000066. eCollection 2016.

12.

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, Bögemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Houédé N, Hussain S, Lam E, Polikoff J, Stenzl A, Mainwaring P, Ramies D, Hessel C, Weitzman A, Fizazi K.

J Clin Oncol. 2016 Sep 1;34(25):3005-13. doi: 10.1200/JCO.2015.65.5597. Epub 2016 Jul 11.

PMID:
27400947
13.

32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016.

Langsteger W, Rezaee A, Loidl W, Geinitz HS, Fitz F, Steinmair M, Broinger G, Pallwien-Prettner L, Beheshti M, Imamovic L, Beheshti M, Rendl G, Hackl D, Tsybrovsky O, Steinmair M, Emmanuel K, Moinfar F, Pirich C, Langsteger W, Bytyqi A, Karanikas G, Mayerhöfer M, Koperek O, Niederle B, Hartenbach M, Beyer T, Herrmann K, Czernin J, Rausch I, Rust P, DiFranco MD, Lassen M, Stadlbauer A, Mayerhöfer ME, Hartenbach M, Hacker M, Beyer T, Binzel K, Magnussen R, Wei W, Knopp MU, Flanigan DC, Kaeding C, Knopp MV, Leisser A, Nejabat M, Hartenbach M, Kramer G, Krainer M, Hacker M, Haug A, Lehnert W, Schmidt K, Kimiaei S, Bronzel M, Kluge A, Wright CL, Binzel K, Zhang J, Wuthrick E, Maniawski P, Knopp MV, Blaickner M, Rados E, Huber A, Dulovits M, Kulkarni H, Wiessalla S, Schuchardt C, Baum RP, Knäusl B, Georg D, Bauer M, Wulkersdorfer B, Wadsak W, Philippe C, Haslacher H, Zeitlinger M, Langer O, Bauer M, Feldmann M, Karch R, Wadsak W, Zeitlinger M, Koepp MJ, Asselin MC, Pataraia E, Langer O, Zeilinger M, Philippe C, Dumanic M, Pichler F, Pilz J, Hacker M, Wadsak W, Mitterhauser M, Nics L, Steiner B, Hacker M, Mitterhauser M, Wadsak W, Traxl A, Wanek T, Kryeziu K, Mairinger S, Stanek J, Berger W, Kuntner C, Langer O, Mairinger S, Wanek T, Traxl A, Krohn M, Stanek J, Filip T, Sauberer M, Kuntner C, Pahnke J, Langer O, Svatunek D, Denk C, Wilkovitsch M, Wanek T, Filip T, Kuntner-Hannes C, Fröhlich J, Mikula H, Denk C, Svatunek D, Wanek T, Mairinger S, Stanek J, Filip T, Fröhlich J, Mikula H, Kuntner-Hannes C, Balber T, Singer J, Fazekas J, Rami-Mark C, Berroterán-Infante N, Jensen-Jarolim E, Wadsak W, Hacker M, Viernstein H, Mitterhauser M, Denk C, Svatunek D, Sohr B, Mikula H, Fröhlich J, Wanek T, Kuntner-Hannes C, Filip T, Pfaff S, Philippe C, Mitterhauser M, Hartenbach M, Hacker M, Wadsak W, Wanek T, Halilbasic E, Visentin M, Mairinger S, Stieger B, Kuntner C, Trauner M, Langer O, Lam P, Aistleitner M, Eichinger R, Artner C, Eidherr H, Vraka C, Haug A, Mitterhauser M, Nics L, Hartenbach M, Hacker M, Wadsak W, Kvaternik H, Müller R, Hausberger D, Zink C, Aigner RM, Cossío U, Asensio M, Montes A, Akhtar S, Te Welscher Y, van Nostrum R, Gómez-Vallejo V, Llop J, VandeVyver F, Barclay T, Lippens N, Troch M, Hehenwarter L, Egger B, Holzmannhofer J, Rodrigues-Radischat M, Pirich C, Pötsch N, Rausch I, Wilhelm D, Weber M, Furtner J, Karanikas G, Wöhrer A, Mitterhauser M, Hacker M, Traub-Weidinger T, Cassou-Mounat T, Balogova S, Nataf V, Calzada M, Huchet V, Kerrou K, Devaux JY, Mohty M, Garderet L, Talbot JN, Stanzel S, Pregartner G, Schwarz T, Bjelic-Radisic V, Liegl-Atzwanger B, Aigner R, Stanzel S, Quehenberger F, Aigner RM, Marković AK, Janković M, Jerković VM, Paskaš M, Pupić G, Džodić R, Popović D, Fornito MC, Familiari D, Koranda P, Polzerová H, Metelková I, Henzlová L, Formánek R, Buriánková E, Kamínek M, Thomson WH, Lewis C, Thomson WH, O'Brien J, James G, Notghi A, Huber H, Stelzmüller I, Wunn R, Mandl M, Fellner F, Lamprecht B, Gabriel M, Fornito MC, Leonardi G, Thomson WH, O'Brien J, James G, Hudzietzová J, Sabol J, Fülöp M.

EJNMMI Res. 2016 Apr;6(Suppl 1):32. doi: 10.1186/s13550-016-0168-9. Epub 2016 Apr 18.

14.

The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma.

Schwameis R, Grimm C, Petru E, Natter C, Staudigl C, Lamm W, Koelbl H, Krainer M, Brodowicz T, Reinthaller A, Polterauer S.

PLoS One. 2015 Aug 6;10(8):e0133838. doi: 10.1371/journal.pone.0133838. eCollection 2015.

15.

Tumor suppressor candidate 3 (TUSC3) prevents the epithelial-to-mesenchymal transition and inhibits tumor growth by modulating the endoplasmic reticulum stress response in ovarian cancer cells.

Kratochvílová K, Horak P, Ešner M, Souček K, Pils D, Anees M, Tomasich E, Dráfi F, Jurtíková V, Hampl A, Krainer M, Vaňhara P.

Int J Cancer. 2015 Sep 15;137(6):1330-40. doi: 10.1002/ijc.29502. Epub 2015 Mar 21.

16.

Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.

Lamm W, Natter C, Schur S, Köstler WJ, Reinthaller A, Krainer M, Grimm C, Horvath R, Amann G, Funovics P, Brodowicz T, Polterauer S.

BMC Cancer. 2014 Dec 18;14:981. doi: 10.1186/1471-2407-14-981.

17.

HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells.

Marhold M, Tomasich E, El-Gazzar A, Heller G, Spittler A, Horvat R, Krainer M, Horak P.

Mol Cancer Res. 2015 Mar;13(3):556-64. doi: 10.1158/1541-7786.MCR-14-0153-T. Epub 2014 Oct 27.

18.

The potential evasion of immune surveillance in mucosa associated lymphoid tissue lymphoma by DcR2-mediated up-regulation of nuclear factor-κB.

Anees M, Horak P, Schiefer AI, Vaňhara P, El-Gazzar A, Perco P, Kiesewetter B, Müllauer L, Streubel B, Raderer M, Krainer M.

Leuk Lymphoma. 2015 May;56(5):1440-9. doi: 10.3109/10428194.2014.953149. Epub 2014 Nov 5.

PMID:
25248880
19.

Docetaxel rechallenge after an initial good response in patients with metastatic castration-resistant prostate cancer.

Oudard S, Kramer G, Caffo O, Creppy L, Loriot Y, Hansen S, Holmberg M, Rolland F, Machiels JP, Krainer M.

BJU Int. 2015 May;115(5):744-52. doi: 10.1111/bju.12845. Epub 2014 Dec 29.

20.

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, Ng S, Maio M, Franke FA, Sundar S, Agarwal N, Bergman AM, Ciuleanu TE, Korbenfeld E, Sengeløv L, Hansen S, Logothetis C, Beer TM, McHenry MB, Gagnier P, Liu D, Gerritsen WR; CA184-043 Investigators.

Lancet Oncol. 2014 Jun;15(7):700-12. doi: 10.1016/S1470-2045(14)70189-5. Epub 2014 May 13.

21.

Circulating endothelial progenitor cells in castration resistant prostate cancer: a randomized, controlled, biomarker study.

Fuereder T, Wacheck V, Strommer S, Horak P, Gerschpacher M, Lamm W, Kivaranovic D, Krainer M.

PLoS One. 2014 Apr 22;9(4):e95310. doi: 10.1371/journal.pone.0095310. eCollection 2014.

22.

TUSC3 loss alters the ER stress response and accelerates prostate cancer growth in vivo.

Horak P, Tomasich E, Vaňhara P, Kratochvílová K, Anees M, Marhold M, Lemberger CE, Gerschpacher M, Horvat R, Sibilia M, Pils D, Krainer M.

Sci Rep. 2014 Jan 17;4:3739. doi: 10.1038/srep03739.

23.

IL-24 sensitizes tumor cells to TLR3-mediated apoptosis.

Weiss R, Sachet M, Zinngrebe J, Aschacher T, Krainer M, Hegedus B, Walczak H, Bergmann M.

Cell Death Differ. 2013 Jun;20(6):823-33. doi: 10.1038/cdd.2013.15. Epub 2013 Mar 1.

24.

Loss of the oligosaccharyl transferase subunit TUSC3 promotes proliferation and migration of ovarian cancer cells.

Vaňhara P, Horak P, Pils D, Anees M, Petz M, Gregor W, Zeillinger R, Krainer M.

Int J Oncol. 2013 Apr;42(4):1383-9. doi: 10.3892/ijo.2013.1824. Epub 2013 Feb 12.

PMID:
23404293
25.

Methylation status of TUSC3 is a prognostic factor in ovarian cancer.

Pils D, Horak P, Vanhara P, Anees M, Petz M, Alfanz A, Gugerell A, Wittinger M, Gleiss A, Auner V, Tong D, Zeillinger R, Braicu EI, Sehouli J, Krainer M.

Cancer. 2013 Mar 1;119(5):946-54. doi: 10.1002/cncr.27850. Epub 2012 Oct 23.

26.

HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer.

Perisanidis C, Savarese-Brenner B, Würger T, Wrba F, Huynh A, Schopper C, Kornek G, Selzer E, Ewers R, Psyrri A, Krainer M, Filipits M.

Oral Dis. 2013 Mar;19(2):206-11. doi: 10.1111/j.1601-0825.2012.01972.x. Epub 2012 Aug 14.

PMID:
22891969
27.

[Therapy of castration-resistant prostate cancer].

Rauchenwald M, Bauernhofer T, De Santis M, Füreder T, Höltl W, Kramer G, Krause S, Loidl W, Oismüller R, Reissigl A, Schmeller N, Stackl W, Stoiber F, Krainer M.

Wien Klin Wochenschr. 2012 Aug;124(15-16):538-51. doi: 10.1007/s00508-012-0206-1. Epub 2012 Jul 20. German.

PMID:
22815001
28.

hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer.

Wittinger M, Vanhara P, El-Gazzar A, Savarese-Brenner B, Pils D, Anees M, Grunt TW, Sibilia M, Holcmann M, Horvat R, Schemper M, Zeillinger R, Schöfer C, Dolznig H, Horak P, Krainer M.

Clin Cancer Res. 2011 Dec 15;17(24):7816-27. doi: 10.1158/1078-0432.CCR-11-0408. Epub 2011 Oct 20.

29.

Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression.

Anees M, Horak P, El-Gazzar A, Susani M, Heinze G, Perco P, Loda M, Lis R, Krainer M, Oh WK.

Cancer. 2011 Mar 15;117(6):1172-82. doi: 10.1002/cncr.25504. Epub 2010 Nov 8.

30.

Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients.

Obermayr E, Sanchez-Cabo F, Tea MK, Singer CF, Krainer M, Fischer MB, Sehouli J, Reinthaller A, Horvat R, Heinze G, Tong D, Zeillinger R.

BMC Cancer. 2010 Dec 3;10:666. doi: 10.1186/1471-2407-10-666.

31.

Natural immunity enhances the activity of a DR5 agonistic antibody and carboplatin in the treatment of ovarian cancer.

El-Gazzar A, Perco P, Eckelhart E, Anees M, Sexl V, Mayer B, Liu Y, Mikulits W, Horvat R, Pangerl T, Zheng D, Krainer M.

Mol Cancer Ther. 2010 Apr;9(4):1007-18. doi: 10.1158/1535-7163.MCT-09-0933. Epub 2010 Apr 6.

32.

The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential.

El-Gazzar A, Wittinger M, Perco P, Anees M, Horvat R, Mikulits W, Grunt TW, Mayer B, Krainer M.

Gynecol Oncol. 2010 Jun;117(3):451-9. doi: 10.1016/j.ygyno.2010.02.024. Epub 2010 Mar 15.

PMID:
20227749
33.

BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-beta treatment.

Pils D, Wittinger M, Petz M, Gugerell A, Gregor W, Alfanz A, Horvat R, Braicu EI, Sehouli J, Zeillinger R, Mikulits W, Krainer M.

Gynecol Oncol. 2010 May;117(2):189-97. doi: 10.1016/j.ygyno.2009.12.034. Epub 2010 Feb 26.

PMID:
20189233
34.

Third consensus on medical treatment of metastatic breast cancer.

Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H; Central European Cooperative Oncology Group (CECOG).

Ann Oncol. 2009 Nov;20(11):1771-85. doi: 10.1093/annonc/mdp261. Epub 2009 Jul 16. Review.

PMID:
19608616
35.

[Chemotherapy for prostate cancer].

Rauchenwald M, De Santis M, Fink E, Höltl W, Kramer G, Marei IC, Neumann HJ, Reissigl A, Schmeller N, Stackl W, Hobisch A, Krainer M.

Wien Klin Wochenschr. 2008;120(13-14):440-9. doi: 10.1007/s00508-008-1008-3. German.

PMID:
18726672
36.

Imaging of Primitive Neuroectodermal Tumor (PNET) by Technetium-99m Tetrofosmin.

Karanikas G, Köstler W, Becherer A, Dudczak R, Krainer M, Kletter K.

Sarcoma. 2001;5(4):215-6. doi: 10.1080/13577140120099218.

37.

Targeting signaling pathways in ovarian cancer.

Reibenwein J, Krainer M.

Expert Opin Ther Targets. 2008 Mar;12(3):353-65. doi: 10.1517/14728222.12.3.353. Review.

PMID:
18269344
38.

Linking the ovarian cancer transcriptome and immunome.

Rapberger R, Perco P, Sax C, Pangerl T, Siehs C, Pils D, Bernthaler A, Lukas A, Mayer B, Krainer M.

BMC Syst Biol. 2008 Jan 3;2:2. doi: 10.1186/1752-0509-2-2.

39.

Oncogenic BARD1 isoforms expressed in gynecological cancers.

Li L, Ryser S, Dizin E, Pils D, Krainer M, Jefford CE, Bertoni F, Zeillinger R, Irminger-Finger I.

Cancer Res. 2007 Dec 15;67(24):11876-85.

40.

Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways.

Kirisits A, Pils D, Krainer M.

Int J Biochem Cell Biol. 2007;39(12):2173-82. Epub 2007 Aug 1. Review.

PMID:
17855153
41.

A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.

Krainer M, Tomek S, Elandt K, Horak P, Albrecht W, Eisenmenger M, Höltl W, Schramek P, Stackl W, Zielinski C, Reibenwein J.

J Urol. 2007 Jun;177(6):2141-5; discussion 2145.

PMID:
17509302
42.

In ovarian cancer the prognostic influence of HER2/neu is not dependent on the CXCR4/SDF-1 signalling pathway.

Pils D, Pinter A, Reibenwein J, Alfanz A, Horak P, Schmid BC, Hefler L, Horvat R, Reinthaller A, Zeillinger R, Krainer M.

Br J Cancer. 2007 Feb 12;96(3):485-91. Epub 2007 Jan 23.

43.

Promoter hypermethylation of GSTP1, AR, and 14-3-3sigma in serum of prostate cancer patients and its clinical relevance.

Reibenwein J, Pils D, Horak P, Tomicek B, Goldner G, Worel N, Elandt K, Krainer M.

Prostate. 2007 Mar 1;67(4):427-32.

PMID:
17192910
44.

The medical management of prostate cancer: a multidisciplinary team approach.

Sternberg CN, Krainer M, Oh WK, Bracarda S, Bellmunt J, Ozen H, Zlotta A, Beer TM, Oudard S, Rauchenwald M, Skoneczna I, Borner MM, Fitzpatrick JM.

BJU Int. 2007 Jan;99(1):22-7. Epub 2006 Sep 6. Review. No abstract available.

45.

Second consensus on medical treatment of metastatic breast cancer.

Beslija S, Bonneterre J, Burstein H, Cocquyt V, Gnant M, Goodwin P, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, Van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H.

Ann Oncol. 2007 Feb;18(2):215-25. Epub 2006 Jul 10. Review.

PMID:
16831851
46.

Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5.

Horak P, Pils D, Kaider A, Pinter A, Elandt K, Sax C, Zielinski CC, Horvat R, Zeillinger R, Reinthaller A, Krainer M.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8585-91.

47.

Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival.

Pils D, Horak P, Gleiss A, Sax C, Fabjani G, Moebus VJ, Zielinski C, Reinthaller A, Zeillinger R, Krainer M.

Cancer. 2005 Dec 1;104(11):2417-29.

48.

Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.

Horak P, Pils D, Haller G, Pribill I, Roessler M, Tomek S, Horvat R, Zeillinger R, Zielinski C, Krainer M.

Mol Cancer Res. 2005 Jun;3(6):335-43.

49.

Common death receptor 4 (DR4) polymorphisms do not predispose to ovarian cancer.

Horak P, Pils D, Roessler M, Tomek S, Elandt K, Zeillinger R, Zielinski C, Krainer M.

Gynecol Oncol. 2005 May;97(2):514-8.

PMID:
15863153
50.

Single-agent trastuzumab versus trastuzumab plus cytotoxic chemotherapy in metastatic breast cancer: a single-institution experience.

Köstler WJ, Steger GG, Krainer M, Kornek GV, Locker GJ, Brodowicz T, Marosi C, Singer CF, Hudelist G, Rabitsch W, Wiltschke C, Zielinski CC.

Anticancer Drugs. 2005 Feb;16(2):185-90.

PMID:
15655416

Supplemental Content

Loading ...
Support Center